| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 03/01/2007 | WO2006029343A3 Peptides that selectively home to heart vasculature and related conjugates and methods |
| 03/01/2007 | US20070050855 Immunoglobulin fusion comprising blood glycoprotein with reduced glycosylation for use in prevention and treatment of septic shock, cachexia, viral and parasitic infection, autoimmune, arthritic and/or graft rejection |
| 03/01/2007 | US20070049533 Analogs of peptides corresponding to class I major histocompatibility complex (MHC)-restricted T-cell epitopes that contain amino acid substitutions of norleucine and/or norvaline; intranodal administration a an immunopotentiating agent |
| 03/01/2007 | US20070048794 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 03/01/2007 | US20070048330 Optimized multi-epitope constructs and uses thereof |
| 02/28/2007 | EP1757701A1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1757695A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757694A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757687A1 Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector |
| 02/28/2007 | EP1757311A2 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1756152A2 Biologically active peptide vapeehptllteaplnpk derivatives |
| 02/28/2007 | EP1756141A1 Process for the preparation of peptides |
| 02/28/2007 | EP1755638A1 Multiple agent therapy for sexual dysfunction |
| 02/28/2007 | EP1633381A4 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity |
| 02/28/2007 | EP1539803B1 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity |
| 02/28/2007 | EP1487762B1 Radiofluorination methods |
| 02/28/2007 | EP1436002B1 Use of peptide vectors to improve the immune response to antigens |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1346041B1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 02/28/2007 | EP1320541B1 Tgf-beta inhibitors and methods |
| 02/28/2007 | EP1317551B1 Human phospholipases and polynucleotides encoding the same |
| 02/28/2007 | EP1276491B9 Tamandarin and didemnin analogs and methods of making and using them |
| 02/28/2007 | EP1204679B1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 02/28/2007 | EP0938497B1 Constrained helical peptides and methods of making same |
| 02/28/2007 | EP0833840B1 Hypoxia inducible factor-1 and method of use |
| 02/28/2007 | CN1301994C Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/27/2007 | USRE39496 Kahalalide F and compositions and uses thereof |
| 02/27/2007 | US7183258 Cytolytic agents; side effect reduction |
| 02/27/2007 | US7183081 Nucleotide sequences coding cytokine polypeptide for use in identifying modulator for treatment or arthritis, allergies, infections, inflammation, skin and cell proliferative disorders; wound healing agents |
| 02/27/2007 | US7183060 specific synthetic peptide sequences derived from E. ewingii that can be used in place of purified proteins, partially purified proteins, infected cells, or cell lysates from Ehrlichia species other than E. ewingii |
| 02/22/2007 | WO2007022531A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 02/22/2007 | WO2007021661A2 Ligands of sh3 domains |
| 02/22/2007 | WO2007021572A2 Use of peptides that bind to tpo receptor |
| 02/22/2007 | WO2007021253A1 Compounds and methods for inhibiting hepatitis c virus replication |
| 02/22/2007 | WO2007021016A1 Photoregulated peptide, and method for regulation of peptide-protein complex formation using the photoregulated peptide |
| 02/22/2007 | WO2007020889A1 Novel mucin glycoprotein and use thereof |
| 02/22/2007 | WO2007020636A1 Printable materials |
| 02/22/2007 | WO2007020405A2 Integrin i-domain binding peptides |
| 02/22/2007 | WO2007020386A2 Apoe mimetic agents |
| 02/22/2007 | WO2006086321A3 Antimicrobial hexapeptides |
| 02/22/2007 | WO2004090103A8 Identification of novel nogo-receptors and methods related thereto |
| 02/22/2007 | US20070043206 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/22/2007 | US20070042968 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease |
| 02/22/2007 | US20070042965 Crystallized structure of type IV collagen NC1 domain hexamer |
| 02/22/2007 | US20070042963 Therapeutic peptides |
| 02/22/2007 | US20070042962 Peptide dependent upregulation of telomerase expression |
| 02/22/2007 | US20070041939 Modified cytokines for use in cancer therapy |
| 02/22/2007 | US20070041904 Peptides whose uptake by cells is controllable |
| 02/22/2007 | US20070041903 Modified minigastrin analogs for oncology applications |
| 02/22/2007 | CA2619017A1 Gdnf derived peptides |
| 02/22/2007 | CA2618958A1 Use of peptides that bind to tpo receptor |
| 02/22/2007 | CA2618791A1 Novel mucin-type glycoprotein and use thereof |
| 02/21/2007 | EP1754719A2 Anti-osteopontin antibody and use thereof |
| 02/21/2007 | EP1754714A1 cyclic peptide derivatives as inhibitors of integrin alpha v beta 6 |
| 02/21/2007 | EP1754713A1 apo2l (trail) receptor binding peptides and uses thereof |
| 02/21/2007 | EP1754485A1 Remedy for neurodegenerative diseases |
| 02/21/2007 | EP1754052A1 Modulators of biochemical characteristics |
| 02/21/2007 | EP1753781A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities |
| 02/21/2007 | EP1753776A1 Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents |
| 02/21/2007 | EP1328546B1 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 02/21/2007 | EP1104438B1 Novel anti-diabetic peptides |
| 02/21/2007 | EP1003787B1 Agent for the treatment and/or prophylaxis of microcirculation disorders |
| 02/21/2007 | EP0602046B2 Detection of feline immunodeficiency viruses |
| 02/21/2007 | CN1916020A Peptide antiangiogenic drugs |
| 02/21/2007 | CN1916019A Method for preparing CYP4A11 polypeptide, and antibody for anti human CYP4A11 polypeptide |
| 02/21/2007 | CN1301264C Oxidation resistant bioactive peptide of halobios and preparation method |
| 02/20/2007 | US7179887 Protein with a molecular weight of between 41 55 kD; useful for the development of models of human platelet aggregation |
| 02/20/2007 | US7179790 Brain natriuretic peptide |
| 02/20/2007 | US7179784 Surfactant peptide nanostructures, and uses thereof |
| 02/20/2007 | US7179635 Peptides for use in culture media |
| 02/20/2007 | US7179610 Characterizing the existence of a disease state; particularly to the utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state |
| 02/20/2007 | US7179606 Utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state |
| 02/20/2007 | US7179445 Cobalamin conjugates useful as imaging and therapeutic agents |
| 02/20/2007 | CA2309312C The process for preparing octreotide and derivatives thereof |
| 02/15/2007 | WO2007019401A2 Polypeptides useful for appetite suppression |
| 02/15/2007 | WO2007018843A2 Methods and compositions for diagnosis and treatment of influenza |
| 02/15/2007 | WO2007018199A1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
| 02/15/2007 | WO2007018198A1 Cancer-rejection antigen peptide derived from hsp105 for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
| 02/15/2007 | WO2007018047A1 Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule |
| 02/15/2007 | WO2007017160A1 Biopeptides with anti-hypertensive activity from bovine beta-casein |
| 02/15/2007 | WO2007016777A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | WO2007016763A1 Peptides targeted to protein kinase c isoforms and uses thereof |
| 02/15/2007 | WO2003099854A3 Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
| 02/15/2007 | US20070037749 Administering a N-terminus modified polypeptide derived from the fibrin alpha or beta chain; antiinflammatory agent, anticoagulants; transplant rejection; arteriosclerosis |
| 02/15/2007 | US20070037141 comprise DP178 peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein; inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells |
| 02/15/2007 | US20070036812 polypeptide with binding to antigen and is recognized by cytotoxic T lymphocytes; use as cancer vaccine |
| 02/15/2007 | US20070036811 autoimmune disorders; human leukocyte antigen |
| 02/15/2007 | US20070036751 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 02/15/2007 | CA2659961A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | CA2659958A1 Peptides targeted to protein kinase c isoforms and uses thereof |
| 02/15/2007 | CA2619443A1 Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same |
| 02/15/2007 | CA2618796A1 Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| 02/15/2007 | CA2618028A1 Polypeptides useful for appetite suppression |
| 02/15/2007 | CA2613482A1 Methods and compositions for diagnosis and treatment of influenza |
| 02/14/2007 | EP1752160A2 Epitope sequences |
| 02/14/2007 | EP1751300A2 T-cell death-inducing epitopes |
| 02/14/2007 | EP1751176A1 Cyclopeptide derivatives with anti-integrin activity |
| 02/14/2007 | EP1751175A1 Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| 02/14/2007 | EP1750528A2 Alpha-msh-antagonist didpeptide conjugates |
| 02/14/2007 | EP1417228B1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |